iPSC-Derived Mesenchymal Stem Cell Exosomes for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for atopic dermatitis lack specificity and effectiveness, necessitating a novel therapeutic approach that leverages the enhanced anti-inflammatory properties of induced pluripotent stem cell-derived mesenchymal stem cells and their exosomes to alleviate skin inflammation.
Innovation Solution
A pharmaceutical and cosmetic composition comprising induced pluripotent stem cell-derived mesenchymal stem cells and their exosomes, characterized by increased indoleamine 2,3-dioxygenase expression and reduced inflammatory cytokine secretion, which are used to treat and prevent atopic dermatitis by modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mesenchymal stem cells are used for treating skin diseases, then immunomodulatory effects are achieved, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent applies parameter changes by using induced pluripotent stem cells (iPSCs) with specifically modified characteristics - increased indoleamine 2,3-dioxygenase (IDO) expression and reduced inflammatory cytokine secretion - to enhance the therapeutic efficacy while maintaining immunomodulatory effects for treating atopic dermatitis
Solution Approach 2:
The patent employs a composite approach by combining iPSC-derived mesenchymal stem cells with their secreted exosomes in a single therapeutic composition, leveraging both the direct immunomodulatory effects of the cells and the paracrine signaling molecules to achieve synergistic therapeutic effects
2Measurement precision
If direct therapy for atopic dermatitis is developed, then specific therapeutic effect is achieved, but current therapies lack specificity and effectiveness
Solution Approach 1:
The patent uses exosomes as intermediary carriers that transport bioactive molecules (proteins, lipids, RNA) from iPSC-derived mesenchymal stem cells to target cells, mediating the therapeutic effect with high specificity while maintaining effectiveness through the natural cell-to-cell communication mechanism
3Reliability
If exosomes from conventional mesenchymal stem cells are used, then cell-to-cell communication is facilitated, but therapeutic efficacy is limited
Solution Approach 1:
The patent modifies the exosomes by deriving them from iPSC-derived mesenchymal stem cells that have altered parameters - specifically increased IDO expression and reduced inflammatory cytokine profiles - which programs the exosomes with enhanced immunomodulatory cargo for superior therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition demonstrates improved immunomodulatory function and therapeutic efficacy in alleviating atopic dermatitis symptoms by reducing inflammation and immune response, as shown in animal models, with potential for clinical application.
Implementation Method 1
Exosomes carry (transport) intracellular biomolecules including proteins, bioactive lipids, and RNA (miRNA), thus playing a functional role in mediating cell-to-cell communication and cellular immunity
Implementation Method 2
characterized by increased indoleamine 2,3-dioxygenase expression and reduced inflammatory cytokine secretion
Data Source
AI summary
The present invention may provide a pharmaceutical composition for preventing or treating skin diseases, a cosmetic composition for preventing or improving skin diseases, and a stem cell therapeutic agent, which comprise an induced pluripotent stem cell-derived mesenchymal stem cell (iMSC), a culture thereof, or an exosome isolated from an iMSC or iMSC culture as active ingredients. When the composition of the present invention, etc. is used, it is possible to provide a composition for improving, preventing or treating skin diseases and a stem cell therapeutic agent which have an improved immunomodulating function over conventional mesenchymal stem cells.